N-terminal Pro-Brain Natriuretic Peptide (NT proBNP) as a Predictive Indicator of Initial Intravenous Immunoglobulin Treatment Failure in Children With Kawasaki Disease: A Retrospective Study

Kim, So Youn; Han, Mi Young; Cha, Sung-Ho; Jeon, Yang Bin
December 2013
Pediatric Cardiology;Dec2013, Vol. 34 Issue 8, p1837
Academic Journal
Intravenous immunoglobulin (IVIG) administered in the acute stage of Kawasaki disease (KD) is the standard therapy. Few reports describe nonresponders to initial treatment with IVIG in KD, which remains the most consistent risk factor for coronary artery lesions (CALs). This study aimed to investigate whether the serum level of N-terminal pro-brain natriuretic peptide (NT-proBNP) can be a predictive indicator for identifying patients with KD at higher risk of IVIG treatment failure. In this study, 135 patients with a diagnosis of KD admitted for IVIG treatment were retrospectively enrolled for analysis. Of these 135 patients, 22 were nonresponders who received additional rescue therapy because they had an elevated body temperature 36 h after completion of initial IVIG treatment. The NT-proBNP concentration was significantly higher in the nonresponder group (2,465.36 ± 3,293.24 pg/mL) than in the responder group (942.38 ± 1,293.48 pg/mL) ( p < 0.05). The optimal sensitivity and specificity cutoff point for predicted nonresponders was 1,093.00 pg/mL or higher. The sensitivity and specificity for prediction of IVIG response were respectively 70.0 and 76.5 %. The findings show that NT-proBNP is a helpful marker in determining patients at risk for not responding to initial IVIG treatment. The authors suggest that patients with an NT-proBNP level of 1,093.00 pg/dL or higher are likely to fail initial IVIG and may require further rescue therapy.


Related Articles

  • Advances in Kawasaki disease. Shulman, Stanford T.; Rowley, Anne H. // European Journal of Pediatrics;2004, Vol. 163 Issue 6, p285 

    Unlabelled: Recent studies have increased our understanding of the etiopathogenesis of Kawasaki disease (KD). The inflammatory infiltrate in KD coronary artery aneurysms has been shown to consist of CD8 T lymphocytes, macrophages, and IgA plasma cells, consistent with an immune...

  • Natriuretic Peptide as an Adjunctive Diagnostic Test in the Acute Phase of Kawasaki Disease. Nagib Dahdah; Siles, Ana; Fournier, Anne; Cousineau, Jocelyne; Delvin, Edgard; Saint-Cyr, Claire; Spiegelblatt, Linda; Bonny, Yvette; Vartian, Michèle; Montigny, Martine // Pediatric Cardiology;Aug2009, Vol. 30 Issue 6, p810 

    Coronary arteritis rather than myocardial involvement is typically emphasized in Kawasaki disease (KD). Moreover, the criteria and the usual biological markers oversee the importance of cardiac-specific markers in diagnosing this disease. We sought to study the clinical usefulness of measuring...

  • Treat acute Kawasaki disease with aspirin plus intravenous immunoglobulin to improve coronary outcomes.  // Drugs & Therapy Perspectives;Oct2012, Vol. 28 Issue 10, p16 

    The article focuses on the use of aspirin plus intravenous immunoglobulin (IVIG) in the treatment of acute Kawasaki disease. It states that treatment of the disease should focus on reducing inflammation and discusses the use of other drugs in the treatment like steroids. It discusses...

  • Tissue Doppler Imaging as a Predictor of Immunoglobulin Resistance in Kawasaki Disease. Phadke, Daniel; Patel, Sonali; Dominguez, Samuel; Heizer, Heather; Anderson, Marsha; Glode, Mary; Jone, Pei-Ni // Pediatric Cardiology;Dec2015, Vol. 36 Issue 8, p1618 

    Kawasaki disease (KD) is characterized by myocarditis and left ventricular dysfunction during the acute phase of the illness. Despite treatment with intravenous immunoglobulin (IVIG), a significant number of patients are IVIG resistant. We evaluated KD patients in the acute phase of illness...

  • Clinical Relevance of the Risk Factors for Coronary Artery Inflammation in Kawasaki Disease. Honkanen, V.E.A.; McCrindle, B.W.; Laxer, R.M.; Feldman, B.M.; Schneider, R.; Silverman, E.D. // Pediatric Cardiology;Mar2003, Vol. 24 Issue 2, p122 

    The objective of this study was to determine predictive factors in children with Kawasaki disease (KD) with which we could distinguish the patients with KD who are either at very low risk or at very high risk for coronary artery inflammation (i.e., either patients who do not need intravenous...

  • Late development of coronary artery abnormalities could be associated with persistence of non-fever symptoms in Kawasaki disease. Fukuda, Sayaka; Ito, Shuichi; Oana, Shinji; Sakai, Hirokazu; Kato, Hitoshi; Abe, Jun; Ito, Ryuko; Saitoh, Akihiko; Ichiro Takayama, John // Pediatric Rheumatology;2013, Vol. 11 Issue 1, p1 

    Background: Persistent fever after intravenous immunoglobulin (IVIG) is considered to be a major criterion of IVIG resistance in Kawasaki disease (KD), and a risk factor for the development of coronary artery abnormalities (CAA). However, the importance of persistent non-fever symptoms after...

  • Kawasaki Disease -- An Indian Perspective. SINGH, SURJIT; KAWASAKI, TOMISAKU // Indian Pediatrics;Jul2009, Vol. 46 Issue 7, p563 

    Kawasaki disease (KD) was first reported from Japan in 1967 by a young pediatrician, Tomisaku Kawasaki, while working at the Red Cross Hospital in Tokyo. Soon thereafter, Marian Melish independently reported children with a similar clinical profile from Hawaii in the United States. KD has now...

  • An Unusual Case of Incomplete Kawasaki Disease in an Adolescent Returning From Holiday in Montana. Hyams, Catherine; Day, Thomas; Ramroop, Shiva; Paget, Stephanie; Howard, Sasha; McMillan, Merlin; Vora, Surabhi; Keyser, Paul // Pediatric Cardiology;Oct2012, Vol. 33 Issue 7, p1196 

    Here we present an unusual case of incomplete Kawasaki disease in a 15-year-old boy returning from a holiday with his family in Montana. His symptoms were initial diarrhoea and lethargy, with fever, rash, conjunctivitis, and arthralgia developing during the course of his illness. His condition...

  • Standard-dose and Short-term Corticosteroid Therapy in Immunoglobulin-resistant Kawasaki Disease. Takeshita, Seiichiro; Kawamura,, Youichi; Nakatani, Keigo; Tsujimoto, Hiroshi; Tokutomi, Tomoharu // Clinical Pediatrics;Jun2005, Vol. 44 Issue 5, p423 

    Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose). Five patients responded...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics